

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

**VOLUNTARY ANNOUNCEMENT
INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX**

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, according to the Index Review Results announced by Hang Seng Indexes Company Limited on 21 February 2025, the Company has been selected for inclusion as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited. The change will be implemented after the trading hours on 7 March 2025 and will be effective from 10 March 2025.

The Board is of the view that the inclusion as a constituent of the Hang Seng Composite Index reflects the capital market’s high recognition of the Company’s business performance and value, which is helpful in broadening the Company’s shareholder base and increasing trading liquidity of its shares, and ultimately enhancing its investment value and reputation of the Company in the capital market. For further details, please refer to the relevant index notice(s) published on the website of Hang Seng Indexes Company Limited (<https://www.hsi.com.hk>).

The Board would like to thank the shareholders of the Company (the “**Shareholders**”) and investors for their continued support to the Company. The Company will continue to develop its business and maximize the Company’s value for the Shareholders.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 25 February 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors; and (iii) Dr. Meng Songdong, Ms. Qi Jingyao and Mr. Ran Dong as independent non-executive Directors.